首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   1296136篇
  免费   102860篇
  国内免费   3103篇
耳鼻咽喉   18573篇
儿科学   44665篇
妇产科学   35184篇
基础医学   184014篇
口腔科学   33997篇
临床医学   113832篇
内科学   260390篇
皮肤病学   28350篇
神经病学   101193篇
特种医学   51734篇
外国民族医学   663篇
外科学   198091篇
综合类   31277篇
现状与发展   10篇
一般理论   382篇
预防医学   97496篇
眼科学   28479篇
药学   97409篇
  30篇
中国医学   4322篇
肿瘤学   72008篇
  2019年   10079篇
  2018年   14104篇
  2017年   10993篇
  2016年   11705篇
  2015年   13557篇
  2014年   18484篇
  2013年   27607篇
  2012年   37820篇
  2011年   39826篇
  2010年   24185篇
  2009年   22893篇
  2008年   37790篇
  2007年   40209篇
  2006年   40308篇
  2005年   39101篇
  2004年   38035篇
  2003年   36829篇
  2002年   36149篇
  2001年   64270篇
  2000年   66698篇
  1999年   56533篇
  1998年   15179篇
  1997年   13792篇
  1996年   14227篇
  1995年   13484篇
  1994年   12785篇
  1993年   11811篇
  1992年   44587篇
  1991年   43484篇
  1990年   42234篇
  1989年   40130篇
  1988年   36905篇
  1987年   36244篇
  1986年   33628篇
  1985年   32292篇
  1984年   24152篇
  1983年   20279篇
  1982年   11734篇
  1981年   10696篇
  1979年   21348篇
  1978年   14827篇
  1977年   12536篇
  1976年   11696篇
  1975年   12632篇
  1974年   14668篇
  1973年   14124篇
  1972年   12956篇
  1971年   11734篇
  1970年   11058篇
  1969年   10030篇
排序方式: 共有10000条查询结果,搜索用时 46 毫秒
991.
Peptide-targeted alpha-therapy with 7.4 MBq of (212)Pb-[1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid]-ReO-[Cys(3,4,10),d-Phe(7),Arg(11)]alpha-MSH(3-13) ((212)Pb-DOTA-Re(Arg(11))CCMSH) cured 45% of B16/F1 murine melanoma-bearing C57 mice in a 120-d study, highlighting its melanoma treatment potential. However, there is a need to develop an imaging surrogate for patient-specific dosimetry and to monitor the tumor response to (212)Pb-DOTA-Re(Arg(11))CCMSH therapy. The purpose of this study was to evaluate the potential of (203)Pb-DOTA-Re(Arg(11))CCMSH as a matched-pair SPECT agent for (212)Pb-DOTA-Re(Arg(11))CCMSH. METHODS: DOTA-Re(Arg(11))CCMSH was labeled with (203)Pb in 0.5 M NH(4)OAc buffer at pH 5.4. The internalization and efflux of (203)Pb-DOTA-Re(Arg(11))CCMSH were determined in B16/F1 melanoma cells. The pharmacokinetics of (203)Pb-DOTA-Re(Arg(11))CCMSH was examined in B16/F1 melanoma-bearing C57 mice. A micro-SPECT/CT study was performed with (203)Pb-DOTA-Re(Arg(11))CCMSH in a B16/F1 melanoma-bearing C57 mouse at 2 h after injection. RESULTS: (203)Pb-DOTA-Re(Arg(11))CCMSH was easily prepared in NH(4)OAc buffer and completely separated from the excess nonradiolabeled peptide by reversed-phase high-performance liquid chromatography (RP-HPLC). (203)Pb-DOTA-Re(Arg(11))CCMSH displayed fast internalization and extended retention in B16/F1 cells. Approximately 73% of (203)Pb-DOTA-Re(Arg(11))CCMSH activity internalized after a 20-min incubation at 25 degrees C. After incubation of the cells in culture medium for 20 min, 78% of internalized activity remained in the cells. (203)Pb-DOTA-Re(Arg(11))CCMSH exhibited a biodistribution pattern similar to that of (212)Pb-DOTA-Re(Arg(11))CCMSH in B16/F1 melanoma-bearing mice. (203)Pb-DOTA-Re(Arg(11))CCMSH exhibited a peak tumor uptake of 12.00+/-3.20 percentage injected dose per gram (%ID/g) at 1 h after injection. The tumor uptake gradually decreased to 3.43+/-1.12 %ID/g at 48 h after injection. (203)Pb-DOTA-Re(Arg(11))CCMSH exhibited a peak tumor-to-kidney uptake ratio of 1.53 at 2 h after injection. The absorbed doses to the tumor and kidneys were 4.32 and 4.35 Gy, respectively, per 37 MBq. Whole-body clearance of (203)Pb-DOTA-Re(Arg(11))CCMSH was fast, with approximately 89% of the injected activity cleared through the urinary system by 2 h after injection. (203)Pb showed 1.6-mm SPECT resolution, which was comparable to (99m)Tc. Melanoma lesions were visualized through SPECT/CT images of (203)Pb-DOTA-Re(Arg(11))CCMSH at 2 h after injection. CONCLUSION: (203)Pb-DOTA-Re(Arg(11))CCMSH exhibited favorable pharmacokinetic and tumor imaging properties, highlighting its potential as a matched-pair SPECT agent for (212)Pb-DOTA-Re(Arg(11))CCMSH melanoma treatment.  相似文献   
992.
993.
994.
995.
Although previous studies have shown successful treatment of persistent diarrhea (PD) with the use of yogurt-based diets, some recent ones speculate the need of special formulas for the nutritional management of PD complicated cases. In the present study, we tested the hypothesis that the consumption of 3 lactose-free diets, with different degrees of complexity, is associated with lower stool output and shorter duration of diarrhea when compared with the use of a yogurt-based one on the nutritional management of PD. A total of 154 male infants, aged between 1 and 30 months, with PD and with or without dehydration, were randomly assigned to 1 of 4 treatment groups. Throughout the study, the patients were placed in a metabolic unit; their body weights and intakes of oral rehydration solution, water, and formula diets, in addition to outputs of stool, urine, and vomit, were measured and recorded at 24-hour intervals. Four different diets were used in this study: diet 1, yogurt-based formula; diet 2, soy-based formula; diet 3, hydrolyzed protein-based formula; and diet 4, amino acid–based formula. Throughout the study, only these formula diets were fed to the children. The data showed that children fed the yogurt-based diet (diet 1) or the amino acid–based diet (diet 4) had a significant reduction in stool output and in the duration of diarrhea. The use of an inexpensive and worldwide-available yogurt-based diet is recommended as the first choice for the nutritional management of mild to moderate PD. For the few complicated PD cases, when available, a more complex amino acid–based diet should be reserved for the nutritional management of these unresponsive and severe presentations. Soy-based or casein-based diets do not offer any specific advantage or benefits and do not seem to have a place in the management of PD.  相似文献   
996.
997.
1. In two rabbits subjected to prolonged injections with crystalline egg albumin the antibodies in one showed progressive changes such as noted in an earlier paper; the antibodies in the other did not. 2. The significance of this behavior in the production of sera for therapeutic use is pointed out. 3. Quantitative studies are reported on the low grade or incomplete antibody present in the early stages of immunization of a horse with egg albumin. 4. Quantitative studies on the flocculating antibody from later bleedings from the horse are given, and the dissociation of the soluble pre-zone compounds by rabbit anti-egg albumin is studied. Rough velocity estimations are reported. 5. The bearing of the findings on the mechanism of precipitin and flocculation reactions and of the Danysz effect is discussed in terms of the union of multivalent antigen with multivalent antibody.  相似文献   
998.
999.
1000.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号